Dediabetes Logo
Evidence Hub
Learn what works
Evidence Explorer
Search the complete evidence graph
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Tirzepatide improves glycemic control and weight loss sustainability in type 2 diabetes

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated July 4, 2026

Key finding

For tirzepatide-treated participants achieving HbA1c ≤48 mmol/mol (6.5%) at 52 weeks, 75–84% sustained this until study end.

This study analyzed the sustainability of glycemic control and weight loss with tirzepatide in type 2 diabetes patients, showing significant maintenance of HbA1c and weight loss.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

High Risk

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study analyzed the sustainability of glycemic control and weight loss with tirzepatide in type 2 diabetes patients, showing significant maintenance of HbA1c and weight loss.

Clinical relevance

These findings are significant for clinicians treating type 2 diabetes, as maintaining glycemic control and weight loss is crucial for reducing long-term complications. The sustained effects of tirzepatide may offer a valuable treatment option for patients struggling with diabetes management.

Keep in mind

Unclear effectiveness for some outcomes due to lack of detailed data. Results may not be generalizable beyond the study population. Limited information on long-term safety and efficacy.

Published in

Journal Reference

Publication details and source links for this paper.

Ewan RP, Stefano DP, Imre P, et al. Sustainability of Glycemic Control and Weight Loss with Tirzepatide in Type 2 Diabetes: A Post Hoc Analysis of the SURPASS-4 Trial. Diabetes. 2025;74(10):1850-1862. doi:10.2337/db25-0276

View DOIView on PubMedView on PMC

Main Effects

75–84% of tirzepatide-treated participants maintained HbA1c ≤48 mmol/mol (6.5%) until study end, with a decrease of -2.5 mmol/mol (p=0.001).

79–82% of participants who lost ≥10% of their weight at 52 weeks maintained this loss, with an average reduction of -5 kg (p=0.002).

Diabetes management self-efficacy scores improved significantly by 0.8 points (p=0.03).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Tirzepatide and 1,5-Anhydroglucitol, Body weight, Diabetes management self-efficacy, and 2 more.

This study contributes evidence to

Intervention

Tirzepatide

Outcome

1,5-Anhydroglucitol

Evidence topic

HbA1c Reduction

Primary intervention

Tirzepatide

Primary outcomes

  • 1,5-Anhydroglucitol
  • Body weight
  • Diabetes management self-efficacy

Evidence topics

HbA1c ReductionWeight LossGLP-1 Receptor Agonists

Primary intervention

Tirzepatide

Primary outcomes

1,5-AnhydroglucitolBody weightDiabetes management self-efficacy

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

3

Related topics

5

Evidence pairs

730

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 5 evidence relationships
  • Includes primary outcome data
  • Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

GLP-1 Receptor Agonists and HbA1c

Related evidence

Evidence relationship

GLP-1 Receptor Agonists and Body Weight

Save evidence

Evidence relationship

GLP-1 Receptor Agonists and Fasting Glucose

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

1,5-Anhydroglucitol

Tirzepatide → 1,5-Anhydroglucitol

Tirzepatide → 1,5-Anhydroglucitol

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Body weight

Tirzepatide → Body weight

Tirzepatide → Body weight

Evidence Intelligence™
EvidenceScore™
83
Strong
ImpactScore™
92
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 12 studies
Add to Evidence Tracker

Diabetes management self-efficacy

Tirzepatide → Diabetes management self-efficacy

Tirzepatide → Diabetes management self-efficacy

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Gestational diabetes mellitus incidence

Tirzepatide → Gestational diabetes mellitus incidence

Tirzepatide → Gestational diabetes mellitus incidence

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

HbA1c

Tirzepatide → HbA1c

Tirzepatide → HbA1c

Evidence Intelligence™
EvidenceScore™
83
Strong
ImpactScore™
96
Very Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 13 studies
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Tirzepatide led to a significant decrease in HbA1c levels by -2.5 mmol/mol.
  • Participants experienced an average weight loss of -5 kg, maintained by 79–82%.
  • Self-efficacy in diabetes management improved by 0.8 score.
who this applies

Who this applies to

  • Adults diagnosed with type 2 diabetes.
  • Patients seeking effective weight management solutions.
keep in mind

Keep in Mind

  • The study's findings are based on a specific trial population.
  • Results may not apply to all demographics or diabetes types.
  • Further research is needed to confirm long-term effects and safety.
between the lines

Between the Lines

  • Unclear effectiveness for some outcomes due to lack of detailed data.
  • Results may not be generalizable beyond the study population.
  • Limited information on long-term safety and efficacy.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 83.4 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 32 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
32 supporting studiesUpdated: Aug 2026
View Full Evidence

Does GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists may improve Body Weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 82.7 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
33 supporting studiesUpdated: Aug 2026
View Full Evidence

Does GLP-1 Receptor Agonists improve fasting glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve Fasting Glucose.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    1,5-Anhydroglucitol

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 12 supporting studies with generally consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
12 supporting studiesUpdated: Aug 2026
View Full Evidence

Does GLP-1 Receptor Agonists improve diabetes incidence and prevention?

Moderate Evidence

Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Diabetes Incidence and Prevention.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Gestational diabetes mellitus incidence

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

  • Only a small number of supporting studies are available.
  • Population details are unavailable.
2 supporting studiesUpdated: Aug 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

HbA1c Reduction Evidence HubWeight Loss Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Tirzepatide and HbA1cAll studies on Tirzepatide and Body weightAll studies on Tirzepatide and 1,5-AnhydroglucitolAll studies on Tirzepatide and Diabetes management self-efficacy

Related research

Read related research summaries.

Tirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesDietary interventions improve glycemic control in pre-diabetic patientsInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.